Overview

A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Status:
Unknown status

Trial end date:
2017-07-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to compare overall survival of patients randomized to receiving custirsen in combination with docetaxel (Arm A) with patients randomized to receive docetaxel alone (Arm B).

Phase:

Phase 3

Details

Lead Sponsor:

Achieve Life Sciences
OncoGenex Technologies

Treatments:

Docetaxel